Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
- Submitting institution
-
The University of Leeds
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- UOA1-426
- Type
- D - Journal article
- DOI
-
10.1136/annrheumdis-2015-209057
- Title of journal
- Annals of the Rheumatic Diseases
- Article number
- -
- First page
- 96
- Volume
- 76
- Issue
- 1
- ISSN
- 0003-4967
- Open access status
- Compliant
- Month of publication
- May
- Year of publication
- 2016
- URL
-
https://doi.org/10.1136/annrheumdis-2015-209057
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
13
- Research group(s)
-
-
- Citation count
- 55
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -